Recursion Pharmaceuticals, Inc. IPO prospectus (424B4)
SEC 424B4, prospectus dated 15 April 2021, filed 16 April 2021. The prospectus cover states "Prospectus dated April 15, 2021"; the EDGAR index gives the filing date 2021-04-16.
- Issued by
- No issuing record yet. A missing record is a gap in coverage.
- Authors credited
- No authorship claim recorded yet. The source record lists Recursion Pharmaceuticals, Inc. (filed with the US SEC).
- Dates
- No date claim recorded yet. The source record gives the publication date as 2021-04-15.
- Exact source
- Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock Recursion Pharmaceuticals, Inc. (filed with the US SEC) · published 2021-04-15 · Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Appears in
No collection holds a record about this document yet.
Versions
No other versions of this document are recorded. The evidence applies to the source version listed above. Other versions, such as a preprint, working paper or journal publication, are not identified or substituted.
Documentary relations
Each relation is listed separately. Citing, crediting and reporting the use of a method are different acts, and none of them shows agreement or influence by itself.
Not recorded for this document: cites · cited by · explicitly credits · reports using a method from · method reported as used by · applies parts of · parts applied by · discusses · reports evaluation of. A missing record does not show that the relation does not exist.
What the document states
A limited selection of what this document states, each with its passage. It describes the text, not whether anyone acted on it.
- Statementcompany statement: four clinical stage programs (April 2021)“We have four clinical stage programs and 33 additional programs in various stages of preclinical development.”Risk factorsInspect claim & evidence ↗
- Statementinitial public offering: 24,242,424 Class A shares at $18.00; Nasdaq symbol RXRX“This is the initial public offering of shares of Class A common stock of Recursion Pharmaceuticals, Inc. We are offering 24,242,424 shares of our Class A common stock. The initial public offering price is $18.00 per share.”Prospectus coverInspect claim & evidence ↗
- Statementstated mission: "Decode Biology to Radically Improve Lives"“Our mission is to Decode Biology to Radically Improve Lives.”A Letter from our Co-Founder and CEOInspect claim & evidence ↗
- Statementself-description: "decoding biology" with the goal of "industrializing drug discovery"; Recursion OS and Recursion Map“We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.”Prospectus summary, "Overview"Inspect claim & evidence ↗